Lupus & antiphospholipid syndrome

Catastrophic antiphospholipid syndrome: Clinical characteristics and outcomes in a non-caucasian population — A five-year experience from a single centre

LupusPublished Retrospective cohort study

Authors' conclusion

Our findings reveal a predominance of high-risk, secondary APS-mainly SLE-associated-with thrombocytopenia. Nearly half presented with CAPS as the initial APS manifestation. Limited access to full triple therapy significantly impacted mortality, which decreased from 100% with partial therapy to 21% with complete regimens.

Study context

Population
Patients fulfilling the CAPS classification criteria at a tertiary referral center in Mexico City, January 2019 to December 202374% female
Participants
19 patients
Outcome
Clinical characteristics, treatment strategies, and outcomes of patients diagnosed with CAPS
Methodological detailssingle-centre, tertiary referral center
  • Single-centre
  • Tertiary referral center

Main finding

As reported in the abstract

Clinical characteristics, treatment and outcomes
Primary antiphospholipid syndrome (APS)
6
Concomitant systemic lupus erythematosus (SLE)
11
Low-risk (2019 EULAR aPL titers classification)
7
High-risk (2019 EULAR aPL titers classification)
12
CAPS as first manifestation of APS
47%
Precipitating factors identified (most commonly infections and anticoagulant withdrawal)
94.7%
Arterial circulation affected
74%
Venous circulation affected
68%
Hematologic manifestations
47%
Kidneys affected
42%
Lungs affected
42%
Heart affected
32%
Anticoagulation
84%
Corticosteroids
79%
Plasma exchange
79%
Triple therapy
74%
Overall mortality
42%
Full recovery with no relapses, among survivors
75%

Observational data: associations, not effects.

Original publication

Catastrophic antiphospholipid syndrome: Clinical characteristics and outcomes in a non-caucasian population — A five-year experience from a single centre. Lupus. Published 28 January 2026. doi:10.1177/09612033261422651

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.